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Abstract 
Gene therapy has recently come of age with seven viral vector-based therapies gaining 
regulatory approval in recent years. In tissue engineering, non-viral vectors are preferred 
over viral vectors, however, lower transfection efficiencies and difficulties with delivery 
remain major limitations hampering clinical translation. This study describes the 
development of a novel multi-domain cell-penetrating peptide, GET, designed to enhance 
cell interaction and intracellular translocation of nucleic acids; combined with a series of 
porous collagen-based scaffolds with proven regenerative potential for different 
indications. GET was capable of transfecting cell types from all three germ layers, 
including stem cells, with an efficiency comparable to Lipofectamine® 3000, without 
inducing cytotoxicity. When implanted in vivo, GET gene-activated scaffolds allowed for 
host cell infiltration, transfection localized to the implantation site and sustained, but 
transient, changes in gene expression – demonstrating both the efficacy and safety of the 
approach. Finally, GET carrying osteogenic (pBMP-2) and angiogenic (pVEGF) genes 
were incorporated into collagen-hydroxyapatite scaffolds and with a single 2μg dose of 
therapeutic pDNA, induced complete repair of critical-sized bone defects within 4 weeks. 
GET represents an exciting development in gene therapy and by combining it with a 
scaffold-based delivery system offers tissue engineering solutions for a myriad of 
regenerative indications. 
 
 
 
 
 
 1. Introduction 
Advances in our understanding of genetics, along with the development of new genetic 
sequencing and editing tools, means that personalized precision medicine is now within 
our grasp. Classical gene therapy is a type of precision medicine that can correct or 
restore a specific misspelled nucleic acid sequence by introducing the corrected version. 
Newer approaches include interfering with transcription, pre-mRNA splicing, mRNA 
catabolism or translation, resulting in over-expression or silencing of target genes, 
collectively opening up the entire genome to therapeutic intervention. [1] However, 
nucleic acid-based molecules have high molecular weights, are highly negatively charged, 
and are degraded rapidly in physiological conditions making intracellular delivery a 
major challenge. [2] Viral-based delivery vectors have had millions of years of 
evolutionary optimization making them extremely efficient in intracellular transfer of 
nucleic acids and, following years of enormous promise and equally colossal set-backs, 
seven viral-based gene therapy products have achieved regulatory approval in the past 6 
years, including three in 2017 alone. [3-5] Having potentially overcome safety concerns 
with viral gene delivery, other limitations include limited nucleic acid loading capacity, 
immunogenicity and expense. Non-viral delivery vectors based on lipids, polymers and 
polysaccharides have been developed to circumvent limitations associated with viral 
vectors but the transfection efficiency is typically much lower, therefore, necessitating 
high doses to exert a response which can subsequently lead to off-target effects. Thus, 
there still exists a significant need for safe and efficient non-viral methods for 
intracellular gene delivery.  
Cell-penetrating peptides (CPPs) are a group of structurally and physico-chemically 
diverse peptides but which share two common characteristics; they all contain fewer than 
30 amino acids and they possess a natural ability to traverse the cell membrane. [6-8] 
This ability is not lost when the peptide is bound to a cargo such as proteins, drugs, 
antibodies, plasmid (p)DNA or siRNA and, when combined with their low 
immunogenicity and cytotoxicity, they represent a very promising option for gene 
therapy. It has been 30 years since two separate laboratories independently discovered 
that the transactivator of transcription (TAT) protein of HIV-1 could cross the cell 
membrane; [9, 10] work which led to the discovery that an 11 amino acid sequence of the 
TAT protein, simply called the TAT peptide, was responsible. [11] Six years later, 
Derossi and colleagues showed that the 16 amino acid third helix of the Drosophila 
Antennapedia homeoprotein, later called penetratin, shared the same property. [12] 
Common to both peptides was the high number of positively charged arginine in each 
sequence initiating research into synthetic arginine rich peptide sequences as intracellular 
delivery vectors. [13, 14] Polyarginine, in particular octaarginine (8R) and nonaarginine 
(9R) are examples of synthetic CPPs. [15-18] While the exact mechanism of how CPPs 
gain entry into cells remains unclear – they have been shown to work via active and 
passive mechanisms –the presence of positively charged amino acids are a key factor as 
well as high extracellular concentrations (2-5 μM), therefore a high dose is typically 
required to ensure efficient intracellular translocation. [19] 
To improve intracellular translocation while also lowering the dose required, Dixon and 
colleagues recently developed a multidomain peptide comprised of a glycosaminoglycan 
(GAG)-binding peptide sequence (P21) to stimulate cell membrane interaction, fused 
with an octaarginine (8R), a CPP capable of crossing the cell membrane. [20] As this 
peptide relies on GAG-binding to enhance intracellular delivery efficiency, the concept 
has been termed GAG-binding enhanced transduction (GET). GET is capable of highly 
efficient delivery of a plethora of functional cargos including proteins, antibodies and 
nucleic acids, to a number of different cell types for different applications and most 
importantly, at low doses. [21, 22] Another version of GET, consisting of a 16-residue 
heparan sulfate-GAG binding peptide derived from the fibroblast growth factor 2 (FGF2) 
protein (FGF2B domain); LK15, an amphiphilic pan-nucleic acid interaction sequence; 
and 8R, together called (FLR) was also developed and showed promise in preliminary in 
vitro studies. However, when applied for in vivo delivery to the lung, the GET peptide 
needed to be PEGylated to enhance stability, which reduced transfection efficiency. [23] 
In the development of an efficient system of gene delivery for use in vivo, five key 
criteria need to be considered; 1) ability to efficiently transfect many cells including so-
called ‘difficult too transfect’ cells such as stem cells; 2) low cytotoxicity; 3) localized 
delivery at the target site; 4) therapeutic activity at low doses and 5) evidence of 
therapeutic application. In vivo gene delivery involves the administration of genes either 
systemically or locally. If a gene delivery vector is administered systemically, retention 
time and clearance must be considered due to the short half-life of pDNA in the presence 
of endonucleases. Local administration can reduce these effects and improve retention at 
the site required however, depending on the target tissue, can sometimes cause damage to 
the surrounding tissues such as retinal detachment following sub-retinal injection.[24] 
Hydrocarbon chains have been added to proline-rich CPPs to increase their circulation 
times, [25] while RGD moieties have been added to target specific tissues. [26] Osman 
and colleagues showed that by PEGylating GET-pDNA nanoparticles before delivery to 
mouse lungs, the nanoparticles maintained colloidal stability in physiological fluids and 
induced significantly higher transgene expression when compared to unmodified GET-
pDNA nanoparticles. [23] Another method to control distribution and provide 
nanoparticle protection, and one that is particularly useful in tissue engineering and 
regenerative medicine is to incorporate the nanoparticles into a biomaterial scaffold, 
termed a gene-activated scaffold or matrix. The scaffold then effectively acts as the gene 
delivery device upon implantation allowing for the controlled release of the gene to cells 
as they infiltrate through the three-dimensional matrix. Simultaneously, the scaffold 
provides mechanical support during regeneration and can be custom designed to mimic 
the native extracellular matrix of the tissue it is replacing. This method was first used by 
Fang and colleagues in 1996 [27] and since then many more iterations have been 
developed for different tissue engineering applications including in our laboratory where 
pDNA, siRNA and miRNAs complexed with polyethyleneimine (PEI), 
nanohydroxyapatite (nHA), chitosan or dendrimers have been delivered on collagen-
based scaffolds for a number of different therapeutic indications. [28-37]  
The aim of this study was to develop and optimize a scaffold-based system for the 
localized delivery of the GET peptide allowing for safe, efficient therapeutic gene 
delivery. Specifically, the first aim was to determine the optimal GET-pDNA 
nanoparticle formulation involving physicochemical characterization, in vitro efficacy 
and biocompatibility testing, and in vivo safety and efficacy testing. The second aim was 
to demonstrate the versatility of GET peptide by delivering genes to a number of different 
cell types representing cells from endoderm, mesoderm and ectoderm. Finally, to 
demonstrate the translational potential of GET-pDNA-activated scaffolds, bone 
regeneration was chosen as a specific therapeutic target and GET-pDNA activated 
scaffolds were developed, optimized and tested in vitro before being applied in the repair 
of critical-sized bone defects in vivo. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2. Materials and Methods 
Sigma Aldrich, Ireland, supplied all materials unless otherwise stated. 
2.1 GET-pDNA nanoparticle characterisation 
2.1.1 Peptide synthesis: Peptides were synthesised using solid phase t-Boc chemistry 
and purified to >90% by Protein Peptide Research Ltd (PPR, UK).  
2.1.2 Plasmid propagation: Plasmids encoding the reporter genes Gaussia Luciferase 
(pGLuc; New England Biolabs, Massachusetts, USA) and green fluorescent protein 
(pZsGreen1; TakaraBio), and therapeutic genes bone morphogenetic protein (pBMP-2; 
kindly donated by Prof. Kazihusa Bessho, Kyoto University, Japan) and, vascular 
endothelial growth factor (pVEGF; purchased from Genecopaeia (USA)), all under the 
control of the cytomegalovirus promoter were propagated by transforming One Shot® 
TOP10 Chemically Competent E. coli bacterial cells according to the manufacturer’s 
protocol. pDNA was purified and collected using the Endotoxin free Maxi-prep kit 
(Qiagen, UK).  
2.1.3 GET-pDNA complex formulation: GET-pDNA complexes were formulated at 
three charge ratios of GET to pDNA (CR 3:1, 4:1 and 5:1, simply referred to as CR 3, 4 
and 5 respectively) with the pDNA dose remaining constant at 2 µg. GET was added to 
pDNA and allowed to complex for 15 minutes via electrostatic interaction between the 
LK15 component of the GET peptide and the pDNA. 
2.1.4 GET-pDNA complex characterisation: Dynamic light scattering (DLS) was used 
to measure nanoparticle size and polydispersity and electrophoretic light scattering (ELS) 
was used to measure complex zeta potential (Zetasizer 3000 HS, Malvern, UK). GET-
pDNA nanoparticles were made as described in Section 2.1.3 and the volume was 
brought up to 1 mL using molecular grade water and transferred to a zeta-cell (Malvern, 
UK) for analysis. Measurements were triplicated for three batches of nanoparticles and 
results are the average of three measurements. A SYBRSafe (Biosciences Ireland) 
exclusion assay was used to quantify complexation efficiency. Briefly, GET-pDNA 
nanoparticles were prepared as in Section 2.1.3 and then diluted to 1.5mL with molecular 
grade 20mM NaCl. SYBRSafe DNA stain was then added and the fluorescence signal 
read, in triplicate, on a spectrofluorimeter (Perkin Elmer LS 50B) at an excitation 
wavelength of 488nm and an emission wavelength of 522 nm. To visualise the stability 
of GET-pDNA complexes when exposed to “physiological conditions”, GET-pDNA 
nanoparticles were formulated as described in Section 2.1.3 before MgSO4 was added to 
give a final concentration of 0.1µM and the samples were either incubated at 37oC for 4h 
with 8 units of DNase I per 1µg of DNA, or incubated in media containing 10% fetal 
bovine serum (FBS) for 12 h. Each sample was subsequently run on a 1% agarose gel for 
1 hour, along with controls as follows; 1 – Ladder; 2 – pDNA alone; 3 – pDNA alone in 
serum; 4 – pDNA alone in DNase; 5 – GET-pDNA at CR3; 6 – GET-pDNA at CR3 in 
serum; 7 – GET-pDNA at CR3 in DNase; 8 - GET-pDNA at CR4; 9 – GET-pDNA at 
CR4 in serum; 10 – GET-pDNA at CR4 in DNase; 11 – GET-pDNA at CR5; 12 – GET-
pDNA at CR5 in serum; 13 – GET-pDNA at CR5 in DNase. The gels were viewed and 
imaged using Amersham Imager 680 blot and gel imager (GE Healthcare). 
 
2.2 Assessment of GET-pDNA transfection efficiency in 2D monolayer, within 3D 
collagen-based scaffolds and when implanted in vivo 
2.2.1 Cell culture: Certified mesenchymal stem cells isolated from bone marrow of 
Sprague Dawley rats were purchased from Cyagen (USA) and cultured in growth media 
containing high glucose (4.5 g/L) Dulbecco's Modified Eagles Medium (DMEM) 
supplemented with 2% penicillin/streptomycin, 10% FBS (Labtech, UK), 1% glutamax, 
and 1% non-essential amino acids. Cells were passaged at 70-90% confluency and 
expanded to passage 5 for all experiments. Human bone marrows were purchased from 
Lonza (Switzerland) and mesenchymal stem cells were isolated using standard protocols 
and stringent analysis of cell phenotype (tri-lineage differentiation and a full panel of cell 
surface markers), as described previously. [38] hMSCs were cultured in low glucose (1 
g/L) Dulbecco's Modified Eagle Medium (DMEM), supplemented with 10% foetal 
bovine serum (FBS) and 1% penicillin/streptomycin. Cells were passaged upon reaching 
80–90% confluency and used in experiments at passage 5. MC3T3 cells were cultured in 
alpha MEM and supplemented with 10% FBS, 1% penicillin/streptomycin and 1% 
Glutamax (Gibco, Ireland) and used at passage 12. Human articular chondrocytes were 
purchased from Lonza (Switzerland) and were cultured in serum-free chondrocyte growth 
media to passage 4 before being used in experiments. C2C12 cells, a mouse 
musculoskeletal progenitor line, were expanded in high glucose DMEM supplemented 
with 10% FBS, 2% penicillin/streptomycin, 1% Glutamax and 1% non-essential amino 
acids and used in experiments at passage 6. Human dermal fibroblasts were purchased 
from ATCC (USA) and cultured in low glucose DMEM supplemented with 10% FBS 
and 1% penicillin/streptomycin and used in experiments at passage 5. Human Umbilical 
Vein Endothelial Cells (HUVECs) were purchased from Lonza (Switzerland) and 
expanded in EGM-2 BulletKit (also Lonza). HUVECs were used in experiments at 
passage 5. The Claycomb lab provided the HL-1 cardiac cell line and cells were cultured 
using previously published protocols and materials. [39] Ne4C cells (ATCC, USA), a 
mouse neuroectodermal cell line was cultured in alpha MEM supplemented with 10% 
FBS, 1% penicillin/streptomycin and 1% Glutamax. 
2.2.2 Transfection of cells with GET-pDNA: Cells were seeded in monolayer at a 
density of 0.5 x 106 cells per well on tissue culture-treated plastic 24 h prior to 
transfection. GET-pDNA nanoparticles were formulated as described in Section 2.1.3 at 
CR 3, 4 and 5, all carrying 2 g of pDNA. Cell growth media was changed immediately 
before transfection and GET-pDNA was added directly to the media at a volume of 50 
L per well. Lipofectamine® 3000 (Invitrogen) was used as a control to represent 
commercially available vectors and was used as per manufacturers recommendations and 
a 2 g pDNA dose. 
2.2.3 Gene-Activated Scaffold Fabrication: Four different collagen-based scaffolds – 
collagen alone, collagen-glycosaminoglycan (chondroitin-6-sulfate) (Coll-GAG), [40] 
collagen hyaluronic acid (CHyA) [41] and collagen-hydroxyapatite (CHA) [42] were 
fabricated using a lyophilisation technique developed by O’Brien et al. [43] The scaffolds 
were cross-linked dehydrothermally (DHT) at 105 °C for 24 h at 0.05 bar in a vacuum 
oven (Vacucell 22; MMM, Germany), [44] followed by chemical cross-linking using a 
mixture of 6 mM N-(3-Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride 
(EDC) and 5.5 mM N-Hydroxysuccinimide (NHS). GET-pDNA complexes were soak-
loaded onto each scaffold to make gene-activated scaffolds. A 8mm biopsy punch was 
used to cut the scaffold to size and scaffolds were hydrated in PBS prior to use. GET-
pDNA complexes at each CR and carrying 2 g of pDNA (Section 2.1.3) were soak-
loaded onto each scaffold to make gene-activated scaffolds. In non-adherent tissue 
culture plates, 0.5 x 106 cells were seeded onto each scaffold and following a 30 minute 
incubation, the wells were flooded with media and incubated at 37C with 5% CO2. 
2.2.4 Assessment of transfection efficiency using reporter plasmids: GET-pGFP 
nanoparticles were formulated as described in Section 2.1.3 at CR 3, 4 and 5 all carrying 
2 g of pGFP. Following transfection as described in Section 2.2.2, fluorescent 
microscopy was used to visualise cells expressing GFP using a Leica DMIL microscope 
(Leica Microsystems, Switzerland). The cells were then fixed in 5% formalin and GFP+ 
cells were quantified using FACS Canto 11 with FlowJo software.  
Due to difficulties with removing cells from the gene-activated scaffolds (Section 2.2.3) 
to quantify GFP+ cells, scaffolds were instead loaded with GET-pGLuc. Gaussia 
Luciferase is a luminescent protein that is secreted into the medium. Therefore, following 
transfection with GET-pGLuc, samples of media were removed at each time-point and 
luciferase content was assessed using a Pierce™ Gaussia Luciferase Flash Assay kit 
(Thermo Scientific, Ireland) as per manufacturer’s instructions.  
2.2.5 Measurement of cell viability post-transfection: Metabolic activity was 
determined using a MTT Cell Growth assay (Millipore™, Ireland) performed at day 3 
post-transfection as described previously. [30] Briefly, 10 μL of MTT reagent was added 
to the cells in 90 μL of media and incubated for 4 h at 37 °C. The supernatant was 
removed and 50 μL of dimethyl sulfoxide (DMSO) was added to dissolve the formazan 
crystals, formed by metabolically active cells, leaving behind a purple colour. The 
intensity of the resulting colour was read at an absorbance of 570 nm using a reference 
wavelength of 630 nm using a Varioskan Flash multimode plate reader (Fisher Scientific, 
Ireland). Colour intensity emitted by untransfected cells was set at 100% and the GET-
treated groups were calculated in relation to the untransfected control. A PicoGreen 
dsDNA kit (Invitrogen, Biosciences, Ireland) was used according to the manufacturer’s 
instructions to estimate DNA concentration and therefore cell proliferation at days 1, 3, 7 
and 14 post-transfection. Cells or scaffolds was placed in sodium carbonate buffer 
containing 0.1% Triton X-100 to lyse cells. DNA concentration was deduced using a 
standard curve.  
2.2.6 Assessment of transfection efficiency of gene-activated scaffolds following 
subcutaneous implantation in vivo: Envigo, UK supplied adult male Wistar rats. The 
subcutaneous implant experiments were conducted in accordance with protocols 
approved by the Research Ethics Committee of the Royal College of Surgeons in Ireland 
(REC 1354) and by the Health Products Regulatory Authority (Project authorization No. 
AE19127/P037) in compliance with EU directive 2010/EU/63. Four longitudinal skin 
incisions (1 cm) were made bi-laterally (2 per side; a total of 4 per animal) along the rat 
spine, with a minimum gap space of 1cm between incisions. The subcutaneous space was 
opened to create a pocket and the scaffold was placed inside before the skin was sutured 
using 4.0 Vicryl absorbable sutures (n=3). At 3, 7, and 14 days post-implantation, the 
animals were anesthetized using inhalational isoflurane before coelenterazine was 
injected subcutaneously. After 5 minutes bioluminescence was imaged using an in vivo 
imaging system (IVIS: Perkin Elmer, UK) for 1 minute using optimized optics and 
resolution settings. The intensity of bioluminescence by endogenous cells was measured 
using Perkin Elmer Living Image software. The signal intensity is represented by 
radiance (p/sec/cm2/sr), which refers to the number of photons per second that are leaving 
a square centimeter of tissue and radiating into a solid angle of one steradian (sr). 
2.3 Investigating the therapeutic efficacy of GET-pDNA-activated scaffolds using 
bone regeneration as a case study 
For in vitro studies, rMSCs were cultured as described in Section 2.2.1. The therapeutic 
plasmids chosen – pBMP-2 and pVEGF, were propagated as described in Section 2.1.2. 
GET-pBMP-2 (CR4; 2 µg of pBMP2), GET-pVEGF (CR4; 2 µg of pVEGF) or GET-
pDual (CR4; 1 µg of pBMP-2 and 1 µg of pVEGF) were prepared as described in Section 
2.1.3. Collagen hydroxyapatite scaffolds [42] were used in this part of the study and 
prepared as described in Section 2.2.3. 
2.3.1 Enzyme-Linked Immunosorbent Assay (ELISA) for BMP2 and VEGF 
Quantification Post-Transfection: ELISAs (R&D Systems, UK) were used to quantify 
the levels of BMP-2 and VEGF protein expressed by cells transfected with each gene as 
well as the combination of both genes (pDual). The cell culture supernatant was collected 
and analysed at days 3, 7, 10 and 14. Assays were carried out according to the 
manufacturer’s instructions and the absorbance of each sample was read at 450 nm using 
a Varioskan Flash multimode plate reader (Fisher Scientific, Ireland) and the quantity of 
BMP-2 and/or VEGF protein present was deduced by calculating against a standard curve.  
2.3.2 MSC Osteogenesis differentiation assay: Cells were cultured in 2D monolayer or 
on scaffolds in growth media (GM control), or osteogenic media (OM) consisting of 
DMEM supplemented with 10% FBS, 1% penicillin/streptomycin, 10mM β-
glycerophosphate, 50µM ascorbic acid-2-phosphate and 100nM dexamethasone. In 2D 
culture, alkaline phosphatase activity was quantified at day 7 post-transfection using a 
SensoLyte® pNPP Alkaline Phosphatase assay kit (Cambridge Biosciences, Ireland). 
Calcium deposition was assessed at day 14 post-transfection using a Stanbio calcium 
CPC Liquicolour assay (Stanbio Inc., USA). In 3D gene-activated scaffold studies, 
calcium deposition was assessed by staining 7 µm sections of paraffin embedded samples 
using alizarin red as described previously [32, 33] and calcium content was quantified as 
in 2D experiments.  
2.3.3 In vivo calvarial defect repair: Envigo, UK supplied adult male Wistar rats for in 
vivo experiments. The calvarial critical-sized defect model experiments were conducted 
in accordance with protocols approved by the Research Ethics Committee of the Royal 
College of Surgeons in Ireland (REC 1350) and by the Health Products Regulatory 
Authority (HPRA) (Project authorization No. AE19127/P036) in compliance with EU 
directive 2010/EU/63. The surgical procedure has been described previously. [32, 33] 
Four weeks post-implantation, samples were harvested and analysis of new bone 
formation was performed using microCT and histomorphometry as described previously 
(n=8). [32] New blood vessel formation was quantified by staining endothelial cells using 
CD31 antibody as described previously (n=8). [32] 
2.4 Statistical analysis: Results are expressed as mean ± standard deviation unless stated 
otherwise. Statistics were carried out using Graphpad Prism software using a general 
linear model ANOVA with Bonferroni or Tukey post-hoc analysis performed for 
multiple comparisons. p≤0.05 values were considered statistically significant where * 
p<0.05, ** p<0.01 and *** p<0.001. 
3. Results and Discussion 
The purpose of using GET was to facilitate intracellular translocation of a therapeutic 
cargo, in this case, plasmid DNA (pDNA). The first aim of this study was therefore to 
characterize GET-pDNA complexes at different formulations to assess suitability for 
transfection. When complexed with pDNA at charge ratios of 3, 4 and 5, the diameter of 
the GET-pDNA nanoparticles progressively increased from 119 ± 7.1 nm (CR3) to 167 ± 
5.5 nm (CR5) as determined using dynamic light scattering (Figure 1A). The zeta 
potential also increased minimally with increasing CR from 26.2 ± 0.1 mV at CR3 to 30 
± 0.3 mV at CR5 (Figure 1B). Size and zeta potential are normally crucial factors in 
determining the transfection efficiency of a non-viral gene delivery vector, [45-47] 
however, as GET contains a cell-penetrating peptide sequence, size becomes less 
important. Nevertheless, nanoparticles within the size-range reported in this study will 
serve only to enhance the transfection efficiency of GET-pDNA nanoparticles.  
What remains a critical point with cell-penetrating peptides is the complexation 
efficiency of pDNA to the GET peptide. Arginine-rich CPPs can be conjugated to pDNA 
by covalent or non-covalent methods; covalent conjugation is most often used because 
the disulfide bridge formed between the CPP and cargo is easily cleaved in the reductive 
environment of the endosome, releasing the cargo. [48] However, this method is 
unsuitable for the delivery of large nucleic acids like pDNA. Non-covalent conjugation is 
used less often and relies on electrostatic charge interaction between the CPP and pDNA, 
which can be inefficient. The inclusion of LK15 in the FLR GET peptide used in this 
study enhances the condensation of pDNA into nanoparticles, protecting the pDNA from 
degradation. It has previously been reported that the binding efficiency of GET to pDNA 
is over 90%, [23] and this was also observed in this study with complexation efficiency 
increasing with CR from 82 ± 4.6% at CR3,  91 ± 3.4% at CR4 to 94.5 ± 1 at CR5 as 
measured using a SYBRSafe exclusion assay (Figure 1C). SYBRSafe is a pDNA stain 
that emits a fluorescent signal upon intercalating between base pairs of DNA. However, 
if the DNA has already bound to the GET peptide, the fluorescent signal will be 
quenched. Previously, polymeric and polysaccharide-based gene delivery vectors have 
fully complexed pDNA into nanoparticles. [28, 30, 36] The gel electrophoresis study 
(Figure 1D) demonstrated that the pDNA is safely complexed with GET as the 
negatively charged pDNA is immobilized within the gel when complexed to GET at CR3, 
4 and 5 (wells 5, 8 and 11 respectively). Furthermore, when incubated in serum-
containing media for 12 h at 37°C, the pDNA remains complexed with GET (CR3: lane 6, 
CR4: lane 9, CR5: lane 12) and the complexation is stable even following incubation 
with DNase for 4 h at 37°C (CR3: lane 7, CR4: lane 10, CR5: lane 13). This is in contrast 
to uncomplexed pDNA which runs towards the positively charged anode at the end of the 
gel (lane 2) and is completely denatured by DNase (lane 4).  
 
 
 
 Figure 1. Physicochemical characterisation of GET-pDNA complexes. The GET peptide contains three 
segments, a heparan sulfate-GAG binding domain, an amphiphilic region which binds to pDNA, and a cell 
penetrating peptide domain to facilitate cell entry. The GET-pDNA complexes (2 µg pDNA) had an 
average diameter of 100-160nm as shown by DLS (A). The zeta potential of GET-pDNA complexes 
increased with increasing CR from approximately 25 mV (CR3) to 30 mV at CR5 (B). The complexation 
efficiency was 82-95% as measured using a SYBRSafe exclusion assay (C) and this level of complexation 
was sufficient to protect the pDNA from degradation when challenged with serum for 12h or DNase for 4 h 
(D). 1 – Ladder; 2 – pDNA alone; 3 – pDNA alone in serum; 4 – pDNA alone in DNase; 5 – GET-pDNA 
at CR3; 6 – GET-pDNA at CR3 in serum; 7 – GET-pDNA at CR3 in DNase; 8 - GET-pDNA at CR4; 9 – 
GET-pDNA at CR4 in serum; 10 – GET-pDNA at CR4 in DNase; 11 – GET-pDNA at CR5; 12 – GET-
pDNA at CR5 in serum; 13 – GET-pDNA at CR5 in DNase. Data plotted represents mean ± SD where n=3. 
One-way ANOVA followed by Tukey post hoc analysis was performed and ** indicates p<0.01 while *** 
indicates p<0.001.   
 
 
To confirm that the addition of the GAG-binding domain is indeed helping with 
transfection, each individual component of the GET peptide, namely F (FGF2B; the 
heparan sulfate-binding domain), L (LK15; the nucleic acid interaction sequence) and R 
(8R; the octaarginine cell penetrating peptide sequence), as well as dual combinations; 
FL, FR and LR, were complexed pGFP and the percentage of GFP+ cells was quantified 
after 3 days and compared to FLR at CR3. Mesenchymal stem cells (MSCs) were chosen 
for the optimization process as they represent a ‘difficult-to-transfect’ primary cell type. 
[49, 50] Figure 2A clearly shows that the addition of the GAG-binding domain 
significantly enhances transfection efficiency by approximately 30%. The next best 
efficiency was with LR at 8.2  0.8%. The relatively low efficiency of LR is due to the 
low dose of 8R used and highlights that the addition of the GAG-binding domain 
improves intracellular translocation.  
As all three formulations of GET-pDNA (CR3, CR4 and CR5) possessed excellent 
physicochemical characteristics, the next step was to compare the transfection efficiency 
and biocompatibility of GET with a commercially available gold standard non-viral 
vector, namely Lipofectamine 3000 (Biosciences, Ireland). While Lipofectamine 
3000 had the highest transfection efficiency at 72.3  1.9%, transfection efficiency was 
also high in GET-pGFP transfected cells at all CRs reaching efficiencies of 48.8 ± 7.7%, 
62 ± 5% and 42.8 ± 5.3% for CR3, 4 and 5 respectively which is exceptionally high for a 
non-viral vector particularly in stem cells (Figure 2B). Indeed, there was no statistically 
significant difference between the transfection efficiency of GET at CR4 versus 
Lipofectamine 3000. 
As well as being efficient, it is critical that gene delivery vectors do not induce significant 
cytotoxicity. In general, non-viral vectors tend to have a better safety profile than viral 
gene delivery vectors, [51] however, some lipid and polymer-based vectors have been 
shown to cause significant cytotoxicity. An MTT assay was used to measure cell 
metabolic activity post-transfection and compared to untransfected cells serving as the 
100% viable control. As shown in Figure 2C, cell metabolic activity in GET transfected 
cells was not significantly different to the control 3 days post-transfection with cell 
viability of 92.8 ± 18%, 90 ± 0.5% and 82 ± 14.7% respectively for CR3, 4 and 5. 
Lipofectamine 3000 transfected cells had a cell viability of 64 ± 15.6% which, while 
not as bad as what has been reported in the past with other lipid-based vectors, was 
significantly lower than GET at CR4, further highlighting the potential of this vector.  
It is also important to know the transfection dynamics of a gene delivery vector over time. 
Figure 2D shows representative images of cells at 1, 3, 7, and 14 days post-transfection 
with GET-pGFP. GFP positive cells are evident following transfection at CR3, 4 and 5 at 
all time-points. These cells were then removed from the wells and fixed before being 
analyzed using flow cytometry which paints a clearer picture of the transfection 
efficiency and GFP expression dynamics (Figure 2E). It surpasses transfection 
efficiencies reported with many commercially available vectors such as Lipofectamine 
2000, [52-54] PEI, [28, 55] chitosan, [30, 56] as well as CPPs, [57, 58] and other novel 
peptide-based macromolecular structures such as PAMAM dendrimers and star-shaped 
and hyperbranched polymers, [36, 59] by up to 20%. Transfection peaked at day 3 at all 
CR and the transfection was transient with a gradual decrease to approximately 40 ± 5% 
by day 7 and 25 ± 6% by day 14. Though not desirable when long-term gene correction is 
required, transient gene expression is ideal for tissue engineering applications as it allows 
for controllable over-expression of therapeutic proteins for a pre-determined amount of 
time to induce repair.  
The cell-penetrating peptide in GET is poly-arginine (8R), an essential amino acid for 
tissue growth that has been shown to enhance cell proliferation. [60-62] In this study, cell 
proliferation rate was not affected, either positively or negatively, following treatment 
with GET-pGFP between transfected and untransfected cells up to 14 days post-
transfection (Figure 2F). This is likely due to the lower concentration of 8R required 
when used in combination with the FGF2B-based peptide sequence and indicates that 
GET-pDNA nanoparticles are highly efficient for gene delivery with minimal disruption 
to the cell cycle.  
It is important to note that all transfections presented in Figure 2 were carried out in 
serum-containing media. Many commercially available gene delivery vectors, including 
Lipofectamine® 3000, work best in serum-free media, thus subjecting cells to unnatural 
serum starvation, which cannot be replicated in vivo. As GET-pDNA nanoparticles are 
efficient in the presence of serum, the translational potential of this vector is even more 
impressive. 
 
Figure 2. Effect of CR on transfection efficiency. Transfection efficiency of each component of the GET 
peptide was compared (2 µg pGFP) to showing that addition of the GAG-binding domain significantly 
improved transfection efficiency (A). CR4 induced significantly higher transfection efficiency than CR3 
and 5 (p<0.05). Lipofectamine® 3000 also induced significantly higher GFP expression than CR3 and 5 
(p<0.001) but was not significantly different to CR4 (B). Cell metabolic activity was higher in cells 
transfected with GET compared to Lipofectamine® 3000, significantly so versus GET-pGFP at CR4 (C). 
Long-term transfection efficiency of GET-pGFP at CR 3, 4 and 5 (2µg pGFP) was assessed using 
fluorescent microscopy (D). Green cells indicate positive transfection. The percentage of cells expressing 
GFP was quantified using flow cytometry (E). Cell viability post-transfection was measured using DNA 
quantification as a marker of cell proliferation (F). There was positive transfection at all CR and cell 
proliferation remained normal with no significant difference compared to untransfected controls over time. 
Data plotted shows mean ± standard deviation (n=3) and * indicates p<0.05, ** p<0.01 and *** p<0.001.  
 
We have shown that GET can protect pDNA from DNase degradation (Figure 1D) 
however; the salt concentration of physiological fluids can reduce electrostatic 
compulsion between nanoparticles resulting in aggregation and activation of the immune 
response. [63, 64] For this reason, we want to develop a scaffold-based delivery system 
that can both shield the GET-pDNA nanoparticles while also retaining the nanoparticles 
at the required site. The use of a biomaterial scaffold delivery system is advantageous, 
especially in tissue engineering applications where the scaffold functions in delivery and 
also provides a template for repair. The composition of the scaffold is important when 
considering the target tissue and within our lab we have developed a series of collagen-
based scaffolds designed to mimic the native extracellular matrix of many tissues while 
allowing for cell infiltration, proliferation and in some cases, differentiation. [40-42, 65, 
66] Moreover, these scaffolds can be manufactured into a variety of shapes to fit specific 
tissues. [67-69] In order to test the versatility of the GET peptide for pDNA delivery; this 
study involved incorporating GET-pDNA nanoparticles into four different collagen-based 
scaffolds, namely, collagen, collagen chondroitin sulfate (CCS), collagen hyaluronic acid 
(CHyA) and collagen hydroxyapatite (CHA). Collagen and CCS scaffolds are applicable 
for multiple tissues such as bone, cartilage, skin and heart valve among others. [70-72] 
CHyA has successfully been applied for use in cartilage, respiratory and nerve tissue 
engineering [41, 68, 73-75] while CHA was designed to mimic bone tissue and this 
particular scaffold has achieved CE approval in Europe and is in use in human patients. 
[42, 76-78] GET-pDNA nanoparticles were successfully and homogenously incorporated 
into each scaffold type as can be seen in SEM micrographs in Figure 3 Ai-Di. MSCs 
proliferated well on all scaffolds and no significant difference in cell number was 
observed over 28 days when the GET gene-activated scaffold was compared to gene-free 
controls (Figure 3 Aii-Dii). When MSCs were cultured on the gene-activated scaffolds, 
transgene expression was rapid and high peaking at approximately day 7 with 6x105 ± 
3.4x104 RLU at CR4 in all but the CHA scaffold (Figure 3 Aiii-Diii). Luciferase 
expression was sustained for 21-28 days post-transfection with no significant difference 
between CR3, CR4 or CR5. Interestingly, transfection was lowest on the CHA scaffold 
reaching a peak of approximately 1x105 ± 1.6x104 which is in line with previous results 
using different vectors. [30] Further studies have shown that hydroxyapatite binds to 
many factors and slows their release (Walsh and Raftery et. al. under review), which, in 
the case of expressed growth factors, ultimately enhanced bioactivity.  
 Figure 3. Effect of GET-activated scaffolds on MSC proliferation and comparison of transfection 
efficiency. GET-pDNA complexes at CR3, 4 and 5 (2µg pDNA) were incorporated into four different 
scaffolds; collagen alone (A), collagen-chondroitin sulfate (CCS) (B), collagen hyaluronic acid (CHyA) (C) 
and collagen hydroxyapatite (CHA) (D) and imaged using scanning electron microscopy. Representative 
images shown in A(i)-D(i) and show homogenous distribution of particles within the scaffolds. Cell 
proliferation on gene-activated scaffolds was not affected with the presence of GET-pDNA (CR5; 2 μg 
pGLuc) relative to gene-free controls (A(ii)-D(ii)). Relative Gaussia Luciferase gene expression was 
monitored over time from MSCs seeded onto GET-pGLuc-activated scaffolds at CR 3, 4 and 5 (2µg 
pGLuc) (A(iii)-D(iii)). Transgene expression is sustained for up to 28 days and a CR of 4 appears to be 
optimal.  Data plotted shows mean ± standard deviation (n=3). 
Having established that GET-pDNA nanoparticles can be incorporated into different 
types of collagen-based scaffolds and maintain their high transfection efficiency, the next 
step was to determine if the gene-activated scaffolds were capable of transfecting 
endogenous cells when implanted acellularly in vivo, thus confirming the translational 
applicability of the system. For this study the collagen chondroitin sulfate (CCS) scaffold 
was used as it is arguably the most versatile of the scaffolds described earlier, having 
been used for bone, cartilage, skin and heart valve applications previously. [41, 71, 72, 
79] The collagen hydroxyapatite (CHA) scaffold was also tested as it has been 
successfully used for bone repair in small and large animal models and is currently in use 
in human patients. [77, 78, 80] The reporter gene encoding Gaussia Luciferase (pGLuc) 
was used as it allows transgene expression to be monitored over time using live in vivo 
luminescence imaging software. The use of live bioluminescence imaging is a validated 
and consistent method of evaluating transcription and translation of genes by host cells 
after in vivo delivery and is a reliable tool for measuring biodistribution of the substrate. 
[81] As before, the GET-pDNA nanoparticles were incorporated into the scaffold, 
forming gene-activated scaffolds, before implantation subcutaneously on the dorsum of 
male Wistar rats. As the transfection efficiencies of GET-pDNA at CR3, 4 or 5 were 
similar in in vitro culture, all CRs were tested in vivo and bioluminescence was read at 
day 3, 7 and 14 post-implantation. What is immediately obvious is that luciferase 
expression is localised at the site of implantation and there was minimal evidence of 
expression elsewhere in the animals (Figure 4). There is background bioluminescence 
evident in the empty controls due to injection of coelenterazine but this was significantly 
lower than GET-pGLuc-activated scaffolds and was subtracted from the test groups. This 
result signifies that the scaffold-based gene delivery system was capable of retaining the 
GET-pGLuc nanoparticles at the site of implantation and indicates that this is a safe 
method for gene delivery as the risk of off-target affects was negated. When the intensity 
of bioluminescence was quantified, the peak in transfection efficiency occurred at day 3 
and 7, similar to in vitro results, followed by a gradual decline. Interestingly, luciferase 
expression was higher on the CHA scaffold reaching 5.9x105 ± 2x105 by day 7 at CR4 
(Figure 4B) when compared to the CCS scaffold 3.9x105 ± 1.5x105 (Figure 4A). This is 
in direct contrast to the in vitro luciferase expression results (Figure 3 B versus D) but is 
likely due to the faster degradation rate of the scaffolds in vivo compared to in vitro and 
supports our hypothesis that expressed proteins become sequestered by the 
hydroxyapatite particles in the CHA scaffold and actually, transfection efficiency on this 
scaffold is similar to the others.  Encouragingly, luciferase expression was maintained up 
to day 14 in the CHA scaffolds particularly those carrying GET-pGLuc at CR4 which 
indicates that as well as providing a safe delivery method, the scaffold is also functioning 
in protecting the GET-pGLuc nanoparticles from degradation. This is extremely 
important as unmodified poly-arginine-based CPPs tend to get excreted rapidly when 
administered systemically. [23, 82] Furthermore, in studies where pDNA was injected 
interperitoneally without a vector, the pDNA accumulated in the liver and kidneys with a 
peak in transgene expression after 24 h followed by a rapid decline. [81] From the results 
presented in Figures 1-4, GET-pDNA nanoparticles carrying 2 g of pDNA at CR4 
performed the best and was designated as the optimal formulation and used in all further 
experiments. Encouragingly, CR4 performed well throughout the earlier in vitro 
experiments in 2D monolayer and in 3D culture, validating these methods used to test 
non-viral gene delivery vectors.  
 
 
 Figure 4. Efficacy of GET-pDNA activated scaffolds in vivo. In vivo transfection efficiency and 
biodistribution following implantation of cell-free GET-pGLuc activated CCS scaffolds (A) and CHA 
scaffolds (C) at CR3, 4 and 5 (2µg pGLuc) into male Wistar rats (n=3). Luciferase expression was 
monitored over time by emitted light displayed as a pseudo-color image overlaying a black-and-white 
photograph of each rat at days 3, 7 and 14 post-implantation. Luciferase expression appears localized to 
implant site at transfection is transient. Luminesence signal intensity is represented by radiance 
(p/sec/cm2/sr) and was quantified using Perkin Elmer Living Image software. GET-pGLuc at CR4 induced 
significantly higher luciferase expression by cells on the CCS scaffold at day 7 (B) and at each time-point 
on the CHA scaffold (D). and transfection is transient peaking at day 3. GET-pGLuc complexes at CR4 
(2µg pGLuc) induce the most transgene expression. Data plotted shows mean ± SEM where n=3. * 
represents p<0.05 and ** p<0.01  
To further emphasize the versatility of the GET peptide as a gene delivery vector, GET-
pGFP nanoparticles, formulated at CR4 carrying 2 μg of pGFP, were delivered to a series 
of different cell types representing different tissues from all three germ layers. This is 
important as many gene delivery vectors show excellent transfection efficiency 
characteristics in specific cell lines such as HeLa, NIH3t3 or HEK293T cells but not in 
primary cells – which limits the translational applicability of the vector. Furthermore, 
some vectors can be cell specific. Human MSCs are a notoriously difficult cell type to 
transfect but with GET-pGFP nanoparticles the transfection efficiency was approximately 
28.5±1.8% at day 3, following a similar trend to what was observed in rat MSCs (Figure 
5A(i) and (ii)). This is higher than what has previously been reported in our group using 
PEI, a gold-standard non-viral gene delivery vector. [83] To represent bone cells, a well-
established osteoblast cell line, MC3T3-E1, was used and transfection efficiency reached 
approximately 20.7±4% at day 3 (Figure 5B(i) and (ii)). Yamano et al. compared the 
transfection efficiency of six different commercially available gene delivery vectors on 
MC3T3-E1 cells including Arrest-In™, ExpressFect™, FuGene® HD, jetPEI®, 
Lipofectamine® 2000, and SuperFect® although different methods were used to 
determine transfection efficiency, namely luciferase expression rather than FACS 
analysis of GFP+ cells, making it difficult to draw comparisons. [84] The same study by 
Yamano and colleagues also compared the transfection efficiency of these well-known 
vectors in C2C12 cells, a mouse myoblast cell line chosen to represent muscle in the 
experiment presented in Figure 5D(i) and (ii). Unlike Yamono’s results, in our study 
C2C12 cells were transfected more readily than MC3T3-E1 cells with transfection 
efficiencies of 43.8±2.8% at day 7. Primary human articular chondrocytes have been 
transduced using a number of different viral vectors including retroviral, lentiviral, 
adenoviral and adeno-associated viral vectors. However, they are less commonly 
transfected using non-viral vectors. FuGene® 6 has a reported transfection efficiency of 
up to 20% when used with hyaluronidase treatment which is comparable to the 20±1.7% 
transfection efficiency achieved with GET in this study (Figure 5C(i) and (ii)). [85] 
Nucleofection has been used to achieve transfection efficiencies of up to 70%, albeit with 
20% cell death post-treatment, and oligofectamine delivering a 5 times higher pDNA 
dose than that reported in this study had a transfection efficiency of approximately 40% 
[86] which indicates that GET can be further optimized for hAC transfection. In a study 
by Dickens et al. in 2010, transfection efficiency of five vectors; Effectene®, FuGene® 
HD, Lipofectin®, PEI and nucleofection, were compared following transfection of 
human dermal fibroblasts (hDFs) and human endothelial progenitor cells (hEPCs) 
derived from peripheral blood. [87] FACS analysis of GFP expression 48h post-
transfection showed efficiencies of approximately 10% with each vector while 
nucleofection resulted in about 45% of cells expressing the transgene. The transfection 
efficiency of these vectors in EPCs was very variable, reaching 45% with Effectene® and 
0% when PEI was used. This study compares favorably with our results which show a 
transfection efficiency of 16.1±1.5% in hDFs at day 3 (Figure 5E(i) and (ii)) and 
46.5±3.5% in human umbilical vein endothelial cells also at day 3 (Figure 5F(i) and (ii)), 
again comparable to commercially available vectors. HL-1 cells are a cardiomyocyte cell 
line which have been successfully transfected with Lipofectamine® 2000 carrying siRNA 
previously [88] resulting in approximately 68% silencing of the target gene. We could not 
find any reports of pDNA delivery to HL-1 cells (Figure 5G(i) and (ii)), or Ne4C cells 
(Figure 5H(i) and (ii)), a mouse neuroectodermal cell line with potential for 
neurogenesis and gliogenesis, where transfection efficiency was quantified in a way that 
can be compared to this study. However, the 15.1±3.5% and 33±2.8% is relatively high 
and demonstrates that GET-pDNA particles are efficient in many different cell types.  
Within our own lab we have compared GET-pDNA to chitosan (NovaFect®; Mw 7.3kDa, 
N/P 20) and PEI (Mw 25kDa, N/P 7) as well as Lipofectamine® 3000 shown in Figure 2, 
and found that GET was transfected approximately 20% more cells when delivering 2 g 
of pGFP to rMSCs. Taken together, this study demonstrates that without any further 
optimization or modifications, GET-pDNA nanoparticles have transfection efficiencies 
equal to or, in many cases, greater than a number of commercially available gene delivery 
vectors.  
 Figure 5. Assessment of GET-pGFP transfection efficiency in various cell types. GET-pGFP (2µg 
pDNA dose at CR4) proved to be highly versatile with positive transfection in eight different cell types. 
Images A(i)-H(i) depict GFP positive cells on day 3 post-transfection. Graphs A(ii)-H(ii) display the 
corresponding quantification of GFP positive cells on days 1, 3, 7 and 14 which was analyzed using FACS. 
Data plotted represents mean ± standard deviation (n=3).  
 
 
2.1 Development of a GET-pDNA-activated scaffold for bone regeneration 
The clinical translation of bioactive scaffolds for the treatment of large segmental bone 
defects has remained a challenge due to safety and efficacy concerns as well as 
prohibitive costs. The design of an implantable, biocompatible and resorbable device, 
which can fill the defect space, allow for cell infiltration, differentiation and 
neovascularization, while also recapitulating the natural repair process and inducing cells 
to lay down new bone tissue, would alleviate the problems with existing treatments. As 
shown in Figure 4, gene-activated scaffolds can allow for sustained release of therapeutic 
pDNA to cells as they infiltrate the scaffold thereby prolonging the therapeutic timeline 
without additional dosing and also limiting off-target side effects.  In addition, by using 
the osteoconductive CHA scaffold, infiltrating cells will be provided with an extracellular 
matrix similar to native bone tissue. The first use of a gene-activated scaffold for bone 
repair was reported in 1996 using a rat femoral defect model [27] while 20 years later the 
first report of a single patient clinical trial using a gene-activated scaffold to repair a non-
union mandibular defect was published. [89] In the human trial plasmid DNA was 
incorporated into a collagen hydroxyapatite scaffold without a gene delivery vector and at 
a very high dose (1 mg of pDNA). Encouragingly, no inflammation or adverse events 
were reported although the effectiveness of the treatment was limited. We believe that the 
use of a gene delivery vector to protect the pDNA from degradation and reduce the 
pDNA dose required will further enhance the repair process.  
Previous work has shown that by combining delivery of pDNA encoding bone 
morphogenetic protein (BMP) and vascular endothelial growth factor (VEGF) can induce 
rapid repair of critical-sized bone defects. [32, 90, 91] Bone morphogenetic protein-2 
(BMP-2) is one of the most potent inducers of bone formation and has been used to 
stimulate bone formation clinically in spinal fusion procedures. [92] Neo-angiogenesis is 
also extremely important in bone repair as damage to the vasculature can often lead to 
inadequate healing or non-union bone defects. In particular vascular endothelial growth 
factor (VEGF) plays a critical role in endochondral ossification, the process by which 
bone forms from a cartilaginous template in the embryo and in the growth plates of long 
bones. [93, 94] Indeed, many studies on fracture repair kinetics have shown that 
inhibition of VEGF can impair bone healing. [95] To create a direct comparison between 
the efficacy of GET-pDNA-activated scaffolds and previously developed gene-activated 
scaffolds, [32, 90] MSCs were transfected with GET-pBMP-2 (2 μg dose of pBMP-2) 
and GET-pVEGF (2 μg dose of pVEGF), as well as a combination of pBMP-2 and 
pVEGF (1 μg dose of each; total pDNA dose of 2 μg), termed GET-pDual. BMP-2 
protein expression levels were increased following transfection with GET-pBMP-2 and 
GET-pDual but not with GET-pVEGF (Figure 6A) while conversely, VEGF protein 
expression was increased following transfection with GET-pVEGF and GET-pDual but 
not with GET-pBMP-2 (Figure 6B). This study simply shows that protein expression can 
be easily manipulated using GET-pDNA nanoparticles and the earlier transfection 
efficiencies observed when reporter pDNA was delivered can be recapitulated when 
using therapeutic pDNA. To determine if these secreted proteins were having an 
osteoinductive effect on the MSCs, alkaline phosphatase (ALP) activity was measured 7 
days post-transfection (Figure 6C) and calcium deposition was quantified after 14 days 
(Figure 6D). ALP activity was significantly increased in MSCs transfected with GET-
pBMP-2, GET-pVEGF and GET-pDual (p<0.001) and this translated to significantly 
increased calcium deposition by differentiated cells compared to untransfected cells and 
cells transfected with non-osteogenic GET-pGFP (p<0.05). These data compare 
favorably with previously published data using chitosan as a gene delivery vector and 
surpass data where PEI and nanohydroxyapatite was used to deliver these genes. [32, 33, 
90] 
When MSCs were seeded onto gene-activated scaffolds loaded with GET-pBMP-2 (2 μg 
dose of pBMP-2), GET-pVEGF (2 μg dose of pVEGF), and GET-pDual (1 μg dose each 
of pBMP-2 and pVEGF; total pDNA dose of 2 μg) nanoparticles. A visible increase in 
mineralization was evident in scaffolds stained with alizarin red (Figure 6E) and when 
quantified, the amount of calcium produced by MSCs on each gene-activated scaffold 
was 3-4-fold higher than controls (p<0.001). The GET-pDual-activated scaffold induced 
significantly more calcium deposition than scaffolds carrying single genes (p<0.05) 
(Figure 6F). These data are comparable to previously published data on the CHA 
scaffold loaded with chitosan nanoparticles carrying both pBMP-2 and pVEGF with 
approximately 2000 µg of calcium produced by cells [32] and 50% more than that 
reported when a nanohydroxyapatite vector was used. [90] 
 Figure 6. Quantification of therapeutic protein production post-transfection and assessment of 
protein functionality in inducing MSC osteogenesis in 2D monolayer and on 3D CHA scaffolds in 
vitro. MSCs were transfected with GET-pBMP-2 (2 µg pDNA dose), GET-pVEGF (2µg pDNA dose) or 
GET-pDual (1µg pBMP-2 + 1µg pVEGF) and production of BMP-2 and VEGF proteins was monitored by 
ELISA at days 1, 3, 7 and 14 post-transfection. A) BMP-2 protein production was increased in cells 
transfected with GET-pBMP-2 and GET-pDual (A) while VEGF protein production was increased in cells 
transfected with GET-pVEGF and GET-pDual (B). ALP activity in MSCs was measured 7 days post-
transfection and showed that transfection with GET-pBMP-2, GET-pVEGF, and GET-pDual caused a 
significant up-regulation in ALP activity compared to controls (C). D) Calcium deposition was quantified 
14 days post-transfection. Each treatment induced cells to produce significantly more calcium than controls. 
When incorporated into CHA scaffolds, a gene-free scaffold was compared to CHA scaffolds loaded with 
GET-pGFP (2 µg pDNA dose), GET-pBMP-2 (2 µg pDNA dose), GET-pVEGF (2 µg pDNA dose) and 
GET-pDual (1µg pBMP-2 + 1µg pVEGF). Mineral deposition by cells was measured after 28 days by 
staining scaffolds using Alizarin red (E) and calcium deposition was quantified (F). Data plotted represents 
mean ± SD where n=3. * represents p<0.05, ** p<0.01 and *** represents p<0.001. 
 
Having confirmed that the GET-pDNA-activated scaffold is effective in the delivery of 
reporter genes to host cells when implanted in vivo (Figure 4), and can induce an 
osteogenic response by MSCs in vitro (Figure 6), in order to investigate the potential for 
clinical translation of GET-pDNA-activated scaffolds, we chose a rat calvarial critical-
sized bone defect model as a therapeutic target due to our laboratory’s extensive expertise 
with this model – which serves as a rapid, high throughput method for in vivo evaluation 
of bone regeneration. [96] While GET-Dual-activated scaffolds performed significantly 
better than all other groups during in vitro testing, GET-pBMP-2 and GET-pVEGF-
activated scaffolds also induced significantly more calcium deposition by MSCs 
compared to controls and were therefore also included in the in vivo assessment. We have 
previously shown that a 7 mm diameter represents a critical-sized defect in Wistar rats 
with a body weight of between 285-350 g. [32] One defect was created per animal and 
was either left empty (Empty defect), filled with a CHA scaffold without genes (Gene-
free), or CHA scaffolds loaded with GET-pBMP-2 nanoparticles (GET-pBMP-2; 2 g 
pDNA dose at CR4), GET-pVEGF nanoparticles (GET-pVEGF; 2 g pDNA dose at 
CR4) or GET-pBMP-2 and GET-pVEGF nanoparticles (GET-pDual; 1 g of each pDNA 
at CR4). As the CHA is scaffold is inherently osteoinductive due to the presence of 
hydroxyapatite particles, the gene-free scaffold is capable of inducing limited repair of a 
critical-sized defect at 4-8 weeks post-implantation [32, 33, 97, 98] but at 16 weeks post-
implantation in a rabbit radial defect model, the CHA scaffold induced a similar level of 
repair as an autogenous bone graft. [78] To assess if the inclusion of GET-pDNA 
nanoparticles within the scaffold can accelerate bone formation over the gene-free CHA 
scaffold, the early time-point of 4 weeks was chosen in this study and microCT and 
histomorphometry were used to quantify new bone formation.  
What is immediately clear from the 3D microCT reconstructions (Figure 7A) is that the 
empty defect showed very minimal repair after 4 weeks and the gene-free scaffold 
induced limited bone formation. Conversely, each GET-pDNA-activated scaffold 
induced large amounts of new bone formation with the GET-pDual-activated scaffold 
completely bridging the defect. When directly compared to previous studies in bone 
defect repair, GET-pDNA activated scaffolds were capable of doubling the amount of 
new bone formation in the same 4 week timeframe. [32] Interestingly, the GET-pVEGF-
activated scaffold induced significantly more new bone formation compared to the GET-
pBMP-2-activated scaffold (p<0.01). This is in agreement with results from ours and 
other laboratories confirming the critical role an enhanced blood supply has in bone 
repair. [32, 94, 95] The histology and subsequent histomorphometry (Figure 7B) confirm 
these results with mature bone bridging the defect in the GET-pDual-activated scaffold 
and large areas of bone formation evident in the GET-pBMP-2 and GET-pVEGF-
activated scaffolds and to a lesser extent, the gene-free scaffold. Thin fibrous tissue is all 
that is present within the empty defect. Again, when quantified, a similar trend to the 
microCT results is evident with GET-pBMP-2<GET-pVEGF<GET-pDual. VEGF plays a 
central role in neovascularization but also acts as a chemoattractant to osteoprogenitor 
cells such as MSCs and can drive osteogenesis, a phenomenon which may explain why 
the GET-pVEGF containing scaffolds performed so well compared to the more 
established pBMP-2 scaffolds. Furthermore, it has been shown that the presence of 
VEGF can make osteoprogenitor cells more sensitive to BMP-2, thus increasing the 
efficacy of BMP-2 over-expression, which may explain why the GET-pDual group 
outperforms GET-pVEGF and GET-pBMP-2 (p<0.001). [99] 
To investigate if new blood vessel formation is indeed occurring in the pVEGF 
containing scaffolds, we stained for CD31, a marker of endothelial cells and quantified 
the number of new vessels found. In Figure 7C CD31+ endothelial cells are stained in red 
and the representative images confirm the hypothesis that the over-expression of VEGF 
at the defect site induced more blood vessel formation, which subsequently increases cell 
infiltration and new bone formation over GET-pBMP-2 scaffolds. When quantified, there 
were significantly more new blood vessels present in the pVEGF containing gene-
activated scaffolds (p<0.001). 
Taken together, these data show that the GET peptide fulfills all of the requirements for a 
gene delivery vector, being capable of efficient delivery of pDNA to a number of cell 
types form each of the three germ layers, including stem cells, while causing minimal 
cytotoxicity. When incorporated into a scaffold-based delivery device and implanted in 
vivo, the GET-pDNA activated scaffold allows for host cell infiltration, localized 
transfection and sustained, but ultimately transient, transgene expression. When used to 
deliver therapeutic genes, utilizing bone repair as an exemplar indication, low doses of 
both GET and pDNA were sufficient to induce MSC osteogenesis and finally when 
implanted in a critical-sized bone defect, complete repair of the defect was achieved in 
just four weeks in a defect that we know would not heal without intervention and takes 
approximately 12 weeks to heal with the scaffold alone. [78] In summary, the results 
from this study show that GET-mediated gene delivery represents an extremely exciting 
development for the field of gene therapy, and, by combining it with scaffold-based 
delivery systems offers potential tissue engineering solutions for a myriad of regenerative 
indications.  
 Figure 7. Micro-CT and histological analysis of bone repair in a critical-sized calvarial defect 4 weeks 
post-implantation. A) Representative microCT scans of harvested bone showing; empty defect, gene-free 
CHA scaffold, GET-pBMP-2 (2µg dose) activated CHA scaffold, GET-+pVEGF (2µg dose), and GET-
pDual (1µg pDNA dose each of pBMP-2 and pVEGF) activated CHA scaffold. A 6mm area at the center 
of the defect was used to quantify new bone volume (% Bone volume fraction) displayed in graph A 
showing significantly enhanced bone formation in all treatment groups over controls with GET-pDual 
inducing the best repair (*** p<0.001). B) Representative histological section of explants from calvarial 
defects at 4x. Histomorphological analysis confirmed that the GET-pDual activated scaffold significantly 
enhanced and accelerated new bone formation compared to all other groups after 4 weeks (*** p<0.001). 
C) Representative images of CD31-stained endothelial cells and over-lay with DAPI to show cell nuclei 
confirming presence of vessels. More vessels were visible in the defects treated with the GET-pVEGF and 
GET-pDual compared to controls and GET-pBMP-2 after 4 weeks indicating enhanced angiogenesis. The 
average number of vessels per image (3 images per section, 6 sections per animal, 8 animals = 18 images 
per group) was quantified and showed that the defects treated with GET-pVEGF and GET-pDual 
significantly enhanced new vessel formation within the defect site confirming the crucial role of 
angiogenesis in bone regeneration. Data plotted represents mean ± standard deviation (n=8). One-way 
ANOVA followed by Tukey post hoc analysis was performed and * represents p<0.05, ** represents 
p<0.01 and *** represents p<0.001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. Conclusion 
Despite recent success in the field of gene therapy, there is currently no clinically 
approved non-viral gene delivery vector available, due to the difficulty in designing 
vectors capable of safely recapitulating viral vectors. However, non-viral vectors are 
generally easier to produce, less costly, and generally safer, making them extremely 
useful in therapies which do not require long-term changes to the genome, simply short-
term over-expression or silencing of a target sequence. This is particularly true in tissue 
engineering where short-term manipulation of cells can be sufficient to induce tissue 
regeneration. This study demonstrates that GET, a multidomain peptide containing both a 
cell binding sequence and a CPP, fulfills the requirements for the ideal gene delivery 
vector as it is capable of efficiently (62%; comparable to Lipofectamine® 3000) and 
safely delivering pDNA to ‘difficult-to-transfect’ MSCs. When combined with 
biomaterial scaffolds, the GET-pDNA activated scaffolds allowed for host cell 
infiltration, localized transfection, and induced sustained, but overall, short-term changes 
in gene expression. When applied for the treatment of critical-sized bone defects in vivo, 
the GET-pDNA-activated scaffold system essentially acts as a single-treatment 
therapeutic factory by inducing host cells to produce therapeutic osteogenic (BMP-2) and 
angiogenic (VEGF) proteins at physiological levels, resulting in more bone formation at 
an earlier time-point than studies delivering recombinant proteins, [98] without the 
adverse side effects and at a fraction of the cost. GET was also shown to be highly 
versatile, capable of transfecting multiple cell types on different biomaterial substrates 
indicating widespread translational potential in a range of tissue engineering applications.  
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